Cargando…

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection

BACKGROUND: Reducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of major atherosclerotic events among patients with chronic kidney disease (CKD), with no evidence of an excess risk of cancer or death from any non-vascular cause. However, non-randomized data have suggested tha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., Craig, J. C., Jiang, L., Pedersen, T., Baigent, C., Landray, M. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412040/ https://www.ncbi.nlm.nih.gov/pubmed/28460629 http://dx.doi.org/10.1186/s12882-017-0545-2

Ejemplares similares

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients
por: Herrington, William, et al.
Publicado: (2015)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
por: Mafham, Marion M, et al.
Publicado: (2018)

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease
por: Herrington, William, et al.
Publicado: (2017)

Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis
por: Mafham, Marion, et al.
Publicado: (2011)

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial
por: Harper, Charlie, et al.
Publicado: (2021)

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD
por: Morton, Rachael L., et al.
Publicado: (2016)

Impact of CKD on Household Income
por: Morton, Rachael L., et al.
Publicado: (2017)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data
por: Harper, Charlie, et al.
Publicado: (2023)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, Natalie, et al.
Publicado: (2016)

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, Pengfei, et al.
Publicado: (2020)

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
por: Kent, Seamus, et al.
Publicado: (2015)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016)

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
por: Baigent, Colin, et al.
Publicado: (2011)

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, Richard, et al.
Publicado: (2018)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
por: Staplin, Natalie, et al.
Publicado: (2021)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
por: Storey, Benjamin C., et al.
Publicado: (2018)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

Allocated but not treated: the silent 16% – Authors' reply
por: Horby, Peter, et al.
Publicado: (2022)

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology
por: Staplin, Natalie, et al.
Publicado: (2022)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2019)

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
por: Parish, Sarah, et al.
Publicado: (2018)

Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?
por: Khan, Safi U., et al.
Publicado: (2020)

PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
por: Preiss, David, et al.
Publicado: (2016)

When LDL Cholesterol Is Not LDL Cholesterol: LpX, A Clinical Lesson
por: Huygen, Lisa P.M., et al.
Publicado: (2022)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

New and emerging lipid-modifying drugs to lower LDL cholesterol
por: Kosmas, Constantine E, et al.
Publicado: (2021)

Lipid-lowering therapies and achievement of LDL-cholesterol targets
por: Rizzo, Manfredi, et al.
Publicado: (2012)

Can vascular mortality be reliably ascertained from the underlying cause of death recorded on a medical death certificate? Evidence from 2800 adjudicated heart protection study (HPS) deaths
por: Herrington, William, et al.
Publicado: (2015)

Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl"
por: Brown, W Virgil
Publicado: (2001)

Phenotypic and Genetic Characterization of Lower LDL Cholesterol and Increased Type 2 Diabetes Risk in the UK Biobank
por: Klimentidis, Yann C., et al.
Publicado: (2020)

What is the association of COVID-19 with heart attacks and strokes?
por: Mafham, Marion, et al.
Publicado: (2021)

Accelerometer-measured physical activity and functional behaviours among people on dialysis
por: Nawab, Khizr A, et al.
Publicado: (2020)

Streamlined mail-based methods for large randomised trials: lessons learnt from the ASCEND study
por: Mafham, Marion M., et al.
Publicado: (2019)

Targeting LDL Cholesterol With LNA
por: Krieg, Arthur M
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p5lh0icbm45m9j22avamhebdis